Aktienanalyse zu Aura Biosciences, Inc. (AURA)AURAAura Biosciences, Inc.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Aura Biosciences Inc is currently a hold. The stock is priced at $6.30, which is below the analyst price target of $18 from H.C. Wainwright, indicating potential upside. However, the company reported a significant net loss of $45.64 million in Q2 2026, which raises concerns about its financial health. Additionally, the RSI is at 45.43, suggesting it is neither overbought nor oversold, indicating a lack of strong momentum in either direction. The main risk is the widening losses, which have increased by 70% year-over-year, impacting investor confidence.